


Date: 13.11.2025



Vivimed

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of Board Meeting- reg.

The Board of Directors of the Company at its meeting held on November 13, 2025 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter and half year ended September 30, 2025 attached herewith;
2. Auditors's Limited Review Report on the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2025.
3. In view of Covid-19 pandemic and ongoing financial stress, there has been a delay in making timely payment to the financial creditors.


The Government has taken several measures to mitigate the distress caused by the pandemic to micro, small and medium enterprises. Further, to ensure quicker, cost effective and value maximising outcomes for all the stakeholders, the government introduced a pre-packaged insolvency resolution process.


The Insolvency and Bankruptcy Code (Amendment) Ordinance, 2021 allows the Company to file an application to National Company Law Tribunal (NCLT) under pre-packaged insolvency resolution process. Accordingly, the Board of Directors approved filing of Application under Section 54A and other applicable provisions read with Section 10 of the IBC subject to approval of shareholders by way of Special Resolution.

4. Approved the draft EGM Notice for seeking the consent of Members by way of EGM through remote e-voting for making an application under Section 54A and other applicable provisions read with Section 10 of IBC to Hon'ble National Company Law Tribunal, Bengaluru Bench.
5. Status on Revocation of Suspension in trading in equity shares of the Company: The Company submitted all the relevant documents and paid applicable fee, hence it is expecting Revocation of Suspension in trading in equity shares of the Company from stock exchanges in few days.

The Board meeting concluded at 19.00 Hrs.
You are requested to take note of the above.

Yours faithfully
For VIVIMED LABS LIMITED


SANTOSH VARALWAR
MANAGING DIRECTOR



Vivimed Labs Limited
CIN : L02411KA1988PLC009463
Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka-585 403, India
T+91 (0) 8482-232045, F+91 (0) 8482-232436
Email: info@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:
6-3-866/1/G1, 3rd Floor, GMR Towers,
Greelands, Begumpet, Hyderabad
Telangana-500 016, India.
GSTIN: 36AAACV6060A1ZQ
T 91(0) 40-6608-6608, F+91(0) 40-6608-6699

VIVIMED LABS LIMITED						
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2025						
Rs. In Million						
Sl. No.	Particulars	3 Months Ended			H1 FY 25	H1 FY 24
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
						Year Ended 31.03.2025
						(Audited)
	Income From Operations					
1	Revenue from Operations	186.59	179.43	221.60	366.02	467.96
	Total revenue from operations	186.59	179.43	221.60	366.02	467.96
2	Other Income	1.60	3.60	0.27	5.20	0.30
3	Total Revenue (1+2)	188.19	183.03	221.87	371.22	468.26
4	Expenses					
a	Cost of material consumed	60.12	101.14	150.22	161.26	319.76
b	Changes in inventories of finished goods work in progress and stock-in-Trade	38.16	(9.75)	(41.05)	28.41	(65.67)
c	Employee Benefit Expenses	45.83	45.10	50.91	90.93	100.43
d	Finance Costs	16.01	5.22	3.73	21.23	6.24
e	Depreciation and Amortisation Expenses	46.84	47.96	38.62	94.80	76.52
f	Other Expenses	55.68	48.32	69.37	104.00	232.03
	Total Expenses	262.64	237.98	271.80	500.63	669.31
5	Profit before tax (3-4)	(74.45)	(54.95)	(49.94)	(129.41)	(201.05)
6	Tax Expenses					
	Current Taxes	-	-	-	-	-
	Deferred Taxes	-	-	-	-	-
	Total tax expenses	-	-	-	-	-
7	Profit for the period /Year (5-6)	(74.45)	(54.95)	(49.94)	(129.41)	(201.05)
8	Other Comprehensive income					
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	5.79
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	5.79
9	Total comprehensive income (7+8)	(74.45)	(54.95)	(49.94)	(129.41)	(201.05)
10	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	1,658.28
11	Other equity					
12	Earnings per Share (before Extraordinary Items) (of Rs2/- each)					
(a)	Basic	(0.90)	(0.66)	(0.60)	(1.56)	(2.42)
(b)	Diluted	(0.87)	(0.64)	(0.58)	(1.52)	(2.35)

NOTES

- The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 13, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed modified conclusion thereon..
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- Total debt availed from SBI bank has been assigned to Rare Asset Reconstruction Company (ARC) under the SARFAESI Act, 2002. The liability continues to be shown under Borrowings and is payable to Rare ARC
- Deferred tax will be calculated at the end of year.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date :13-11-2025

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

Vivimed Labs Limited		
Balance Sheet as at 30.9.2025		
All amounts in Rs Million		
Particulars	Standalone	
	As At 30-09-2025 (Unaudited)	As At 31-03-2025 (Audited)
ASSETS		
Non current assets		
Property, Plant and Equipment	2386.61	2,478.72
Intangible assets	662.34	674.08
Capital work in progress	171.13	171.13
Financial assets		
Investments	587.73	587.83
Other non-current assets	-	-
Total non current assets	3,807.82	3,911.76
Current assets		
Inventories	500.57	564.99
Financial assets		
Trade receivables	575.51	458.01
Cash and cash equivalents	5.92	2.89
Loans	35.35	54.23
Others	479.72	469.00
Current tax assets, net	99.01	98.22
Other current assets	895.71	830.40
Total current assets	2,591.79	2,477.75
Total assets	6,399.61	6,389.51
EQUITY AND LIABILITIES		
Equity		
Equity share capital	165.83	165.83
Other equity	290.18	419.09
Total equity	456.01	584.92
Non current liabilities		
Financial Liabilities		
Borrowings	633.06	633.16
Others	1071.21	1,100.35
Deferred tax liabilities, net	90.33	90.33
Other Non current liabilities	5.22	5.22
Provisions	40.17	43.49
Total non current liabilities	1,840.00	1,872.55
Current liabilities		
Financial Liabilities		
Borrowings	3117.05	3,115.06
Trade payables	395.34	336.45
Other financial liabilities	21.75	75.39
Other current liabilities	279.00	211.05
Provisions	110.43	14.16
Current tax liabilities	180.03	179.93
Total Current liabilities	4,103.61	3,932.04
Total liabilities	5,943.60	5,804.59
Total equity and liabilities	6,399.61	6,389.51



STANDALONE STATEMENT OF CASH FLOW		
(All amounts in Indian Rupees Millions, except share data and where otherwise stated)		
Particulars	For six months ended 30th September 2025	For six months ended 30th September 2024
I. Cash flows from operating activities		
Profit before tax	(129.41)	(201.05)
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation of tangible assets / Amortisation of intangible assets	94.80	76.52
Finance income (including fair value change in financial instruments)		-
Finance costs (including fair value change in financial instruments)	21.23	6.24
Operating profit before working capital changes	(13.39)	(118.29)
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets		
Trade receivables	(117.50)	(59.69)
Inventories	64.42	44.06
Loans - current	18.88	(26.45)
Other assets - current	(76.03)	71.66
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	58.89	10.69
Other liabilities	(34.23)	117.06
Cash generated from operations	(98.96)	39.04
Income taxes paid	(0.69)	0.33
Net cash generated from/(used in) operating activities	(98.27)	38.71
II. Cash flows from investing activities		
Proceeds from sale/ (Purchase of) property, plant and equipment and intangibles (including capital work in progress), net	112.5	-29.32
Proceeds from sale of Investment	0.10	-
Interest received (finance income)		-
Net cash used in investing activities	112.60	(29.32)
III. Cash flows from financing activities		
Share issue proceeds		-
Dividend paid		-
Proceeds from/(repayment of) long-term borrowings, net	1.89	(3.65)
Proceeds from/(repayment of) short-term borrowings, net		0
Interest paid	(21.23)	-6.24
Provisions	0	-
Net cash provided by financing activities	(19.35)	(9.89)
Net increase in cash and cash equivalents (I+II+III)	(5.02)	(0.50)
Cash and cash equivalents at the beginning of the year	10.94	11.44
Cash and cash equivalents at the end of the year (refer note below)	5.92	10.94
Note:		
Cash and cash equivalents comprise:		
Cash on hand	2.03	2.00
Balances with banks:	3.89	8.94
- in current accounts	5.92	10.94

Handwritten signature/initials

VIVIMED LABS LIMITED						
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2025						
Rs. In Million						
Sl. No.	Particulars	3 Months Ended			H1 FY 25	H1 FY 24
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
						(Audited)
	Income From Operations					
1	Revenue from Operations	206.12	213.88	247.72	420.00	541.45
	Total revenue from operations	206.12	213.88	247.72	420.00	541.45
2	Other Income	2.12	3.78	0.27	5.90	0.87
3	Total Revenue (1+2)	208.25	217.66	247.99	425.91	542.32
4	Expenses					
a	Cost of material consumed	53.02	107.73	154.71	160.75	352.88
b	Changes in inventories of finished goods work in progress and stock-in-Trade	38.16	(9.75)	(41.05)	28.41	(65.67)
c	Employee Benefit Expenses	55.96	57.05	62.85	113.01	123.13
d	Finance Costs	16.55	5.76	4.27	22.31	7.24
e	Depreciation and Amortisation Expenses	49.04	50.13	41.00	99.17	81.09
f	Other Expenses	68.53	61.67	77.62	130.20	247.51
	Total Expenses	281.26	272.58	299.40	553.85	746.18
5	Profit before tax (3-4)	(73.01)	(54.93)	(51.41)	(127.94)	(203.86)
6	Prior Period Expenses					
7	Tax Expenses					
	Current Taxes	-	-	-	-	2.26
	Deferred Taxes	-	-	-	-	(1.13)
	Total tax expenses	-	-	-	-	1.13
8	Profit for the period /Year (5-6)	(73.01)	(54.93)	(51.41)	(127.94)	(203.86)
9	Non Controlling Interest					
10	Other Comprehensive income					
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	4.24
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	0.39
	Total other comprehensive income	-	-	-	-	4.63
	Non Controlling Interest					
11	Total comprehensive income (7+8)	(73.01)	(54.93)	(51.41)	(127.94)	(203.86)
12	Paid up Equity Share Capital	165.83	165.83	165.83	1,658.28	165.83
13	Other equity					
14	Earnings per Share (before Extraordinary Items) (of Rs2/- each)					
	(a) Basic	(0.88)	(0.66)	(0.62)	(1.54)	(2.46)
	(b) Diluted	(0.85)	(0.64)	(0.60)	(1.50)	(2.39)

NOTES

- The above consolidated financial results of Vivimed Labs Limited and its subsidiary company ("the Group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 13, 2025. The statutory auditors of the Group have carried out a limited review on consolidated financial results and expressed modified conclusion thereon.
- These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- Total debt availed from SBI bank has been assigned to Rare Asset Reconstruction Company (ARC) under the SARFAESI Act, 2002. The liability continues to be shown under Borrowings and is payable to Rare ARC
- Deferred tax will be calculated at the end of year.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 13-11-2025

For VIVIMED LABS LIMITED
(SANTOSH VARALWAR)
MANAGING DIRECTOR

Vivimed Labs Limited
Consolidated Balance Sheet as at 30.9.2025

All amounts in Rs Million

Particulars	Consolidated	
	As At 30-09-2025 (Unaudited)	As At 31-03-2025 (Audited)
ASSETS		
Non current assets		
Property, Plant and Equipment	2,447.56	2,544.03
Intangible assets	1,479.08	1,532.68
Capital work in progress	209.69	171.13
Financial assets		
Investments	1,684.85	1,684.95
Other non-current assets	12.96	-
Total non current assets	5,834.15	5,932.79
Current assets		
Inventories	526.97	587.55
Financial assets		
Trade receivables	893.40	741.10
Cash and cash equivalents	10.12	7.08
Loans	499.01	469.26
Others	479.72	485.29
Current tax assets, net	99.01	101.92
Other current assets	897.57	883.34
Total current assets	3,405.80	3,275.54
Total assets	9,239.94	9,208.33
EQUITY AND LIABILITIES		
Equity		
Equity share capital	165.83	165.83
Other equity	(645.46)	(517.52)
Total equity	(479.63)	(351.69)
Non current liabilities		
Financial Liabilities		
Borrowings	633.93	636.15
Others	4,594.61	4,702.28
Deferred tax liabilities, net	90.33	86.20
Other Non current liabilities	5.22	5.22
Provisions	49.48	48.21
Total non current liabilities	5,373.57	5,478.06
Current liabilities		
Financial Liabilities		
Borrowings	3,206.53	3,127.13
Trade payables	461.79	394.25
Other financial liabilities	31.28	118.53
Other current liabilities	355.83	246.64
Provisions	110.54	14.83
Current tax liabilities	180.03	180.58
Total Current liabilities	4,346.01	4,081.96
Total liabilities	9,719.57	9,560.01
Total equity and liabilities	9,239.94	9,208.33

CONSOLIDATED STATEMENT OF CASH FLOW

(All amounts in Indian Rupees Millions, except share data and where otherwise stated)


Particulars	For six months ended 30th September 2025	For six months ended 30th September 2024
I. Cash flows from operating activities		
Profit before tax	(127.94)	(203.86)
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation of tangible assets	99.17	81.09
Amortisation of intangible assets		
Finance income (including fair value change in financial instruments)	22.31	7.24
Finance costs (including fair value change in financial instruments)	(6.46)	(115.53)
Operating profit before working capital changes		
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets		
Trade receivables	(152.30)	(54.54)
Inventories	60.58	34.26
Loans - current	(29.75)	3.90
Other assets - current	(8.66)	49.25
Other assets - Non-current	(12.96)	0.52
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	67.54	31.33
Other liabilities	(86.23)	69.73
Cash generated from operations	(168.24)	18.92
Income taxes paid	(6.49)	(29.90)
Net cash generated from/(used in) operating activities	(161.74)	48.82
II. Cash flows from investing activities		
Proceeds from sale/ (Purchase of) property, plant and equipment and intangibles (including capital work in progress), net	112.5	(41.43)
Interest received (finance income)		-
Net cash used in investing activities	112.50	(41.43)
III. Cash flows from financing activities		
Share issue proceeds		-
Dividend paid		-
Proceeds from/ (repayment of) long-term borrowings, net	77.18	(4.65)
Proceeds from/ (repayment of) short-term borrowings, net		
Interest paid	(22.31)	(7.24)
Net cash provided by financing activities	54.87	(11.89)
Net increase in cash and cash equivalents (I+II+III)	5.63	(4.50)
Cash and cash equivalents at the beginning of the year	15.76	20.26
Cash and cash equivalents at the end of the year (refer note below)	10.13	15.76
Note:		
Cash and cash equivalents comprise:		
Cash on hand	2.12	2.30
Balances with banks:	8.00	13.46
- in current accounts		
	10.12	15.76

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Review report to
THE BOARD OF DIRECTORS
M/S VIVIMED LABS LIMITED


1. We have reviewed the accompanying "statement of Unaudited Standalone Financial Results" (the "statement") of **VIVIMED LABS LIMITED** ("the Company"), for the Quarter and Half Year ended 30 September 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time ("the Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. **Basis for Qualified Conclusion**

Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of ₹ 157.28 million on an accrual basis for the Quarter ended 30.09.2025, (₹ 307.11 million for the year to date 30.09.2025) pertaining to loans. [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards



5. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid 'Ind AS 34' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For SVRL & Co.

Chartered Accountants

Firm's Regn No: 016182S

**RAMAKRISHNA
GADDAM**

Digitally signed by
RAMAKRISHNA
GADDAM
Date: 2025.11.13
19:32:04 +05'30'

Place: Hyderabad

Date: 13-11-2025

G Ramakrishna

Partner

M. No. 213487


UDIN: 25213487BMMMMNB8316

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Vivimed Labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Vivimed Labs Limited

1. We have reviewed the accompanying "Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year Ended 30 September 2025" (the "Statement") of Vivimed Labs Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associates attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.



4. The Statement includes the results of the following entities:

Holding Company

1. Vivimed Labs Limited

Subsidiaries

1. Finoso Pharma Private Limited
2. Vivimed Holdings Limited
3. Vivimed Labs USA INC.
4. Vivimed Labs Mauritius Limited

Associates

1. Yantra Green Power Private Limited


5. **Basis for Qualified Conclusion**

Based on information provided to us by management, holding company has not provided for interest expenses of ₹ 157.28 million on an accrual basis for the Quarter ended 30.09.2025 (₹ 307.11 million for year to date 30.09.2025), pertaining to loans. [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards

6. **Qualified Conclusion**

Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of subsidiaries, whose interim financial results and other financial information reflect total assets of Rs. 6,749.18 million as at 30th September 2025, total revenues of Rs. 19.36 and 53.99 million for the quarter and half year ended September 30,2025 respectively, total net profit after tax of Rs. 1.44 million and 1.47 million for the quarter and half year ended September 30,2025 respectively, as considered in the "Statement" whose interim financial results and other financial information have not been reviewed by their auditors; These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our




conclusion on "the Statement", in so far as it relates to the affairs of subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

Place: Hyderabad

Date:13-11-2025

UDIN: 25213487BMM MNA1954



For SVRL & Co.

Chartered Accountants

Firm's Regn No: 0161825

RAMAKRIS
HNA
GADDAM

Digitally signed by
RAMAKRISHNA
GADDAM
Date: 2025.11.13
19:30:35 +05'30'

G Ramakrishna

Partner

M. No. 213487

STATEMENT OF IMPACT OF LIMITED REVIEW AUDIT QUALIFICATIONS (FOR LIMITED REVIEW REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH UN AUDITED FINANCIAL RESULTS – STANDALONE BASIS – VIVIMED LABS LIMITED

Statement of Impact of Audit Qualifications for the Quarter Ended September 30, 2025 (Regulation 33 / 52 of the SEBI (LODR) (Amendment), Regulations, 2016)

(Rupees in Millions)

	S. No.	Particulars	Un audited Figures(as reported before adjustment)	Adjusted Figures
I	1.	Turnover/ Total Income	188.19	188.19
	2.	Total Expenditure	262.64	419.92
	3.	Net Profit / (Loss)	(74.45)	(231.73)
	4.	Earnings Per Share	(0.90)	(2.79)
	5.	Total Assets	6,399.61	6,399.61
	6.	Total Liabilities	6,399.61	6,399.61
	7.	Net Worth	456.01	148.90
	8.	Any Other Financial Items (as felt appropriate by the Management)	-	-

II	Audit Qualification:
1	a. <u>Details of Audit Qualification:</u> Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of ₹ 157.28 million on an accrual basis, pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards. b. Type of Audit Qualification: Qualified Opinion c. Frequency of Qualification: Recurring d. For Audit Qualification(s) where the impact is quantified by the Auditor, Management's Views: The company is engaged in the negotiations with its bankers for a settlement and is confident for settlement with banks. Hence, the company has not recorded interest on outstanding loan for the Quarter ended 30.09.2025 e. For Audit Qualification(s) where the impact is not quantified by the Auditor: Nil


J. Siva Prasad
Jarugula Siva Prasad

Chairman of Audit Committee

Place: Hyderabad
Date: 13.11.2025

Santosh Varadwar
Santosh Varadwar
Managing Director

Phanindernath Petasanti
Phanindernath Petasanti
Chief Financial Officer



ti C Ramakrishna
RAMAKRISHNA GADDAM
Statutory Auditors
M/s SVRL & Co,
Chartered Accountants


STATEMENT OF IMPACT OF AUDIT QUALIFICATIONS (FOR LIMITED REVIEW AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH QUARTERLY FINANCIAL RESULTS – CONSOLIDATED BASIS – VIVIMED LABS LIMITED

Statement of Impact of Audit Qualifications for the Quarter Ended September 30, 2025 (Regulation 33 / 52 of the SEBI (LODR) (Amendment), Regulations, 2016)


(Rupees in Millions)

	S. No.	Particulars	Unaudited Figures (as reported before adjustment)	Adjusted Figures
I	1.	Turnover/ Total Income	208.25	208.25
	2.	Total Expenditure	281.26	438.54
	3.	Net Profit / (Loss)	(73.01)	(230.29)
	4.	Earnings Per Share	(0.88)	(2.78)
	5.	Total Assets	9,239.94	9,239.94
	6.	Total Liabilities	9,239.94	9,239.94
	7.	Net Worth	(479.63)	(786.74)
	8.	Any Other Financial Items (as felt appropriate by the Management)	-	-


II	Audit Qualification:
1	a. Details of Audit Qualification: Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of ₹ 157.28 million on an accrual basis, pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards. b. Type of Audit Qualification : Qualified Opinion c. Frequency of Qualification : Recurring d. For Audit Qualification(s) where the impact is quantified by the Auditor, Management's Views: The company is engaged in the negotiations with its bankers for a settlement and is confident for settlement with banks. Hence, the company has not recorded interest on outstanding loan for the Quarter ended 30.09.2025 e. For Audit Qualification(s) where the impact is not quantified by the Auditor: Nil


Jarugula Siva Prasad

Chairman of Audit Committee


Santosh Varadwar

Managing Director


Phanindernath Petasonti

Chief Financial Officer

G Ramakrishna

RAMAKRISHNA GADDAM
Digitally signed by
RAMAKRISHNA GADDAM
Date: 2025.11.13 20:40:08
+05'30'

**Statutory Auditors
M/s SVRL & Co,
Chartered Accountants**

Place: Hyderabad

Date: 13.11.2025

